Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ondra Health vs Zealthy

By GLP-1 ScorecardUpdated

Ondra HealthFactor scores not reassessed.
Site position #5

Higher score

ZealthyFactor scores not reassessed.
Site position #513

Lower score

Score comparison

Ondra Health has the higher recorded score — 86.8/100 to 46.7/100.

Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ondra publishes monthly and prepaid compounded injection plans with pharmacy choices; compare the upfront bill, eligible pharmacy and early-cancellation repricing before choosing a term.

Before you choose

Before comparing the headline prices, the Ondra Health review and the Zealthy review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Ondra Health vs Zeuss and Renlo Health vs Zealthy compare each of them with another graded program, and the list of alternatives to Ondra Health ranks the programs closest to Ondra Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the PlexusDx review covers one graded close to these two, at 67.7/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueOndra Health +65
91
26
Dose & formulationOndra Health +20
84
64
Clinical oversightOndra Health +45
86
41
Labs & monitoringOndra Health +31
84
53
FulfillmentOndra Health +22
88
66
Contract termsOndra Health +45
86
41
Ondra Health · top barZealthy · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricOndra HealthZealthy
WeighScore86.8/10046.7/100
GradeBC
Site position#5#513
Semaglutide$149/mo (compounded; month-to-month)$151/mo on a 3-month supply, plus a separate membership (bundle $217 first month, then $297/mo; compounded)
Tirzepatide$219/mo (compounded; month-to-month)From $216/mo, plus a separate membership (bundle $349 first month, then $449/mo; compounded)
CoverageAdvertises 50 states; pharmacy and formulation eligibility varies34 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Ondra Health

Site position #5 · B

Factor scores not reassessed.

Strengths

  • Publishes monthly charges and separate upfront totals for longer plans
  • Allows requests for an eligible pharmacy and formulation, subject to prescribing and availability
  • Names independent clinical partners and advertises provider messaging, supplies and shipping

What to consider

  • Six- and twelve-month plans require prepayment and an eligible Hallandale or Vials prescription
  • Early prepaid cancellation reprices each three-month supply already sent at the regular quarterly rate
  • Confirm the selected renewal cutoff and any earned consultation or administrative fees
  • Branded and oral access, included lab testing and independent current certification were not established
Zealthy

Site position #513 · C

Factor scores not reassessed.

FDAWarning letter issued to FitRX, LLC dba Zealthy in September 2025. See the FDA warning-letter database.

Strengths

  • Serves 34 states — meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

What to consider

  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • FDA issued FitRX, LLC dba Zealthy a warning letter in September 2025; the letter is public in FDA's warning-letter database

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard